Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05511246 · ClinicalTrials.gov registry record · Phase 2
Venous Ethanol for Ventricular Tachycardia
A Phase 2 study of Ventricular Tachycardia and Ischemic Cardiomyopathy, sponsored by The Methodist Hospital Research Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 156
- Enrollment target
- 1
- Study location
NCT05511246: Recruiting Phase 2 study of Ventricular Tachycardia and Ischemic Cardiomyopathy, sponsored by The Methodist Hospital Research Institute.
NCT05511246 is a Phase 2 study of Ventricular Tachycardia and Ischemic Cardiomyopathy that is actively recruiting participants, run by The Methodist Hospital Research Institute. The registered enrollment target is 156 participants, below the 283-participant average among 28 other Ventricular Tachycardia trials with a reported enrollment target (45% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05511246, a Phase 2 study of Ventricular Tachycardia and Ischemic Cardiomyopathy, is actively recruiting participants, sponsored by The Methodist Hospital Research Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 156 participants
- Enrollment target
- 1
- Study location
Study Summary
Comparative effectiveness randomized clinical trial, comparing endocardial radiofrequency ablation alone vs radiofrequency ablation combined with venous ethanol in patients with ischemic ventricular tachycardia -Venous Ethanol for Left Ventricular Ischemic Ventricular Tachycardia -VELVET clinical trial
Primary Outcome
Detection of VT on defibrillator
Conditions Studied
Interventions
- DRUG Venous ethanol
- PROCEDURE Catheter ablation
Study Locations (1)
Texas
- Houston Methodist Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2023-04-12 |
| Est. Completion | 2028-12-12 |
| Phase | Phase 2 |
What NCT05511246 shows while recruiting
NCT05511246 is an interventional study that assigns participants to a tested intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap, below the 283-participant average among 28 other Ventricular Tachycardia trials with a reported enrollment target (45% lower).
The record links to 2 conditions, with Ventricular Tachycardia appearing as the primary indexed condition, and to 2 interventions - of which Venous ethanol is the first listed.
NCT05511246 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05511246 about?
NCT05511246 is a clinical study titled "Venous Ethanol for Ventricular Tachycardia". Comparative effectiveness randomized clinical trial, comparing endocardial radiofrequency ablation alone vs radiofrequency ablation combined with venous ethanol in patients with ischemic ventricular tachycardia -Venous Ethanol for Left Ventricular Ischemic Ventricular Tachycardia -VELVET clinical tr...
What is the current status of trial NCT05511246?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 2023-04-12. Estimated completion is 2028-12-12.
What conditions does trial NCT05511246 study?
This clinical trial studies the following conditions: Ventricular Tachycardia, Ischemic Cardiomyopathy.
What interventions are being tested in trial NCT05511246?
The interventions under investigation include: Venous ethanol (DRUG), Catheter ablation (PROCEDURE).
Who is sponsoring clinical trial NCT05511246?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05511246 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ventricular Tachycardia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05511246's enrollment target sits among peer trials
156 11th of 28 higher than 18 of 28 other Ventricular Tachycardia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ventricular Tachycardia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Trial Utilizing Dantrolene in Patients With Ventricular Arrhythmias.
COMPLETED · Phase 2
-
Ventricular Tachycardia Mechanisms
RECRUITING · NA
-
Randomized Assessment of TcMS for VT Storm
RECRUITING · NA
-
Cardiac Radioablation for VT
RECRUITING · NA
-
Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial Fibrillation
RECRUITING
-
Ablation-Index Guided Scar-Mediated Ventricular Tachycardia Ablation in Patients With Ischemic Cardiomyopathy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03082755 · 156 participants · Phase 4
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
- NCT04047628 · 156 participants · Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- NCT04166877 · 156 participants · Phase 4
Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
- NCT04533464 · 156 participants · Phase 2
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI